950772-08-4

Upstream product

• 72342-87-1 (1r,4r)-4-ethoxycyclohexan-1-amine 
• 77542-18-8 1-methyl-1-ethyl-4-oxopiperidinium iodide 
• 3612-18-8 N-ethyl-4-piperidone 
• 847416-23-3 2-((1R,4R)-4-((tert-butyldimethylsilyl)oxy)cyclohexyl)isoindoline-1,3-dione 
• 950772-07-3 trans-N-(4-ethoxycyclohexyl)phthalimide 
• 99337-98-1 2-((1R,4R)-4-hydroxycyclohexyl) isoindoline-1,3-dione 

Downstream Products

• 950771-79-6 (2-amino-5-methylphenyl){1-[trans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}amine 
• 950771-78-5 1-[trans-4-(ethyloxy)cyclohexyl]-N-(5-methyl-2-nitrophenyl)-4-piperidinamine 
• 1134197-50-4 2-({1-[trans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}amino)-4-methylphenol 

Relevant academic research and scientific papers

COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE

Compounds of formula (I) or a salt thereof are provided: wherein R4, R5, R6, Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.

BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE

Compounds of formula (I), salts and solvates are provided: formula (I), wherein Q, R and R6 are as defined in the claims. Uses of the compounds for therapy, for example in the treatment of psychotic disorders and cognitive impairment, are also disclosed.